{"id":"NCT01660802","sponsor":"Allergan","briefTitle":"Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-04","primaryCompletion":"2014-03-31","completion":"2014-05-20","firstPosted":"2012-08-09","resultsPosted":"2015-06-08","lastUpdate":"2019-04-17"},"enrollment":262,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Edema"],"interventions":[{"type":"DRUG","name":"700 μg Dexamethasone","otherNames":["Ozurdex®"]},{"type":"OTHER","name":"Sham","otherNames":[]}],"arms":[{"label":"700 μg Dexamethasone","type":"EXPERIMENTAL"},{"label":"Sham","type":"SHAM_COMPARATOR"}],"summary":"This study will assess the safety and efficacy of 700 μg dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in patients with macular edema in a 6 month double-blind period versus sham followed by a 2 month open label period.","primaryOutcome":{"measure":"Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye","timeFrame":"Baseline, 6 Months","effectByArm":[{"arm":"700 μg Dexamethasone","deltaMin":60,"sd":null},{"arm":"Sham","deltaMin":31,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":7},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["29119239"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":129},"commonTop":["Intraocular Pressure Increased","Conjunctival Haemorrhage","Conjunctival Hyperaemia"]}}